ALX Oncology Holdings Inc key statistics and ratios
In fiscal 2022, ALX Oncology Holdings Inc had return on equity of -39.4%, debt equal to 4.0% of equity and a current ratio of 9.57. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 |
|---|---|---|---|---|---|
| Operating margin | −662.0% | −400.0% | <−999% | — | — |
| Net margin | −664.3% | −401.2% | <−999% | — | — |
| Free-cash-flow margin | −669.7% | −304.5% | <−999% | — | — |
| Return on equity | — | — | −25.5% | −21.1% | −39.4% |
| Return on assets | — | −180.2% | −20.5% | −20.5% | −36.0% |
| Asset turnover | — | 0.45 | 0.01 | — | — |
| Current ratio | — | 1.97 | 70.28 | 24.00 | 9.57 |
| Debt to equity | — | — | — | 0.0% | 4.0% |
| Interest cover (operating income ÷ interest) | — | — | — | n/m | n/m |
| R&D as % of revenue | 545.2% | 340.0% | >999% | — | — |
| Capital spending as % of revenue | 31.6% | 7.4% | 2.6% | — | — |
| Quarter | 2019 Q2Jun 2019 | 2019 Q3Sept 2019 | 2019 Q4Dec 2019 | 2020 Q1Mar 2020 | 2020 Q2Jun 2020 | 2020 Q3Sept 2020 | 2020 Q4Dec 2020 |
|---|---|---|---|---|---|---|---|
| Operating margin | −323.5% | −241.6% | −637.5% | −800.3% | <−999% | — | — |
| Net margin | −324.1% | −242.4% | −728.4% | −832.7% | <−999% | — | — |
| Free-cash-flow margin | — | −253.7% | −231.8% | <−999% | <−999% | — | — |
| Current ratio | — | — | 1.97 | — | 13.04 | 36.46 | 70.28 |
| Debt to equity | — | — | — | — | — | 2.3% | — |
| R&D as % of revenue | 280.2% | 176.0% | 555.2% | 584.4% | >999% | — | — |
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Compare with peers
More: Biotechnology stocks compared, Health Care sector, rankings of US companies